How researchers are using mRNA to help untangle Alzheimer’s disease.

Why GLP-1 anti-obesity drugs are taking the market by storm.

DRAGONFLY deep learning meets de novo drug design – and Roche has already tested the approach

Drug developers place their bets on the ROR-1 antigen in the battle against solid tumors.

Sending out instrumentation to trade shows or customer locations for demonstration purposes is expensive and not risk free. Enter 3D virtual worlds.

We interview Freya Biosciences' Colleen Acosta about the need for more therapies to address healthcare issues specific to women.

Why the FDA must delete its statement that people are not horses (or cows), referring to ivermectin use

In this video interview, Courtney Silverthorn explains the inspiration behind a free regulatory playbook for gene therapy manufacturers.

Production records written using erasable markers, use of expired raw materials, and more.

Day 3 closes out with sessions on drug delivery devices